Adjuvant antimicrobial effects on human blood samples
Research type
Research Study
Full title
Use of patient derived tissue for the study of novel antimicrobial effects
IRAS ID
321548
Contact name
Neil Kad
Contact email
Sponsor organisation
University of Kent
Duration of Study in the UK
0 years, 6 months, 0 days
Research summary
Cancer chemotherapeutics kill dividing cells, unfortunately, this includes the cells of the immune system. As a result, cancer patients are considerably more prone to microbial infection, and of concern ~27% of infections are caused by multi-drug resistant bacteria. This leads to delays in chemotherapy treatment, and directly risks patients’ health, with particularly high mortality rates for haematological malignancies.
We previously screened over 2700 FDA-approved drugs, and identified 8 that inhibit bacterial growth in the presence of chemotherapeutics. Here, we aim to test these compounds on blood samples drawn from patients with ongoing microbial infection to determine if the drugs can kill the bacteria found in clinical settings.
This is an essential step towards proving the effectiveness of the identified compounds and will be used as the basis for subsequent clinical trials.REC name
South Central - Berkshire B Research Ethics Committee
REC reference
23/SC/0129
Date of REC Opinion
31 Mar 2023
REC opinion
Favourable Opinion